Jazz Pharmaceuticals (JAZZ) legal chief sells 1,192 shares under 10b5-1 plan

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported an open-market sale of 1,192 Ordinary Shares at $236.97 per share. After this transaction, she directly holds 52,626 shares.

The sale was executed automatically under a Rule 10b5-1 trading plan adopted on February 26, 2026, indicating it was pre-scheduled rather than a discretionary trade based on short-term market conditions.

Insider Trade Summary 10b5-1

Net Seller: 1,192 shares

Net Sell 1 txn

Insider Patil Neena M

Role EVP & Chief Legal Officer

Sold 1,192 shs ($282K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,192	$236.97	$282K

Holdings After Transaction: Ordinary Shares — 52,626 shares (Direct)

Footnotes (1)

1. F1. This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Key Figures

Shares sold: 1,192 shares Sale price: $236.97 per share Shares held after sale: 52,626 shares

3 metrics

Shares sold 1,192 shares Open-market sale on May 28, 2026

Sale price $236.97 per share Ordinary Shares transaction

Shares held after sale 52,626 shares Direct ownership following transaction

Key Terms

Rule 10b5-1, open-market sale, Ordinary Shares

3 terms

Rule 10b5-1 regulatory

"plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

""security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/01/2026 - 04:09 PM Learn about SEC filing dates

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Neena M. Patil?

Jazz Pharmaceuticals reported that EVP & Chief Legal Officer Neena M. Patil sold 1,192 Ordinary Shares in an open-market transaction at $236.97 per share, leaving her with 52,626 shares held directly after the sale was completed.

Was the Neena M. Patil share sale in Jazz Pharmaceuticals (JAZZ) discretionary?

The sale was not discretionary. It occurred automatically under a Rule 10b5-1 trading plan that Neena M. Patil adopted on February 26, 2026, meaning the timing and amount were pre-set independent of short-term market movements.

How many Jazz Pharmaceuticals (JAZZ) shares does Neena M. Patil hold after the reported sale?

After selling 1,192 Ordinary Shares, Neena M. Patil directly holds 52,626 Jazz Pharmaceuticals shares. This post-transaction holding figure helps investors understand the scale of the sale relative to her remaining ownership stake in the company.

What price did Neena M. Patil receive per Jazz Pharmaceuticals (JAZZ) share sold?

Neena M. Patil’s open-market sale was executed at $236.97 per Ordinary Share. This per-share price, disclosed in the Form 4, provides transparency into the trading level at which the pre-planned Rule 10b5-1 transaction occurred.

What is the significance of Rule 10b5-1 in the Jazz Pharmaceuticals (JAZZ) insider sale?

Rule 10b5-1 allows insiders to set pre-arranged trading plans. The filing states Patil’s sale followed a Rule 10b5-1 plan adopted February 26, 2026, indicating the transaction was scheduled in advance rather than timed based on non-public or short-term information.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patil Neena M

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/28/2026		S(1)		1,192	D	$236.97	52,626	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	By: /s/Paz Dizon, as attorney in fact For: Neena M. Patil	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)